Meera Mohan

51PUBLICATIONS
97CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene expression (incl. microarray and other genome-wide approaches)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseases
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (51)

|Sep 24, 2026
Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis.

|Apr 14, 2026
Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study.

Doris K Hansen, Danai Dima, Hira Mian

|Mar 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma.

Fredrik Schjesvold, Andrew Spencer, Yael C Cohen

|Dec 18, 2025
Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability.

Meera Mohan, Natalie Danziger, Othman Salim Akhtar

|Nov 07, 2025
Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Samer Al Hadidi, Aniko Szabo, Bhavesh Mohan Lal

|Jul 21, 2025
Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels.

Rahul Banerjee, Meera Mohan, Kai Rejeski

Pageof 9

Frequent Collaborators

21 joint publications

Binod Dhakal

17 joint publications

Anita D'Souza

17 joint publications

Carolina Schinke

11 joint publications

Aniko Szabo